Alvotech Puts Iceland on the SPAC Map

by | Jun 16, 2022

Telehealth-related DA for DHAC, a deal termination for AKIC / DNEG. And the rest of the day’s news in SPACs.

Free Investor Resources from Boardroom Alpha
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Alvotech Debuts today

Icelandic biopharma Alvotech (ALVO) deSPAC’d today from Oaktree Acquisition Corp. II. The public listing ($293M market cap) is the largest debut on a US stock exchange by an Icelandic company. Shares closed at $10.95.

SPAC Deal: DHAC / VSee Lab

Digital Health Acquisition Corporation (DHAC) announces DA with VSee Lab, a telehealth software company and iDoc Telehealth Solutions, a leading neurocritical care and intensive care telehealth provider. The transaction values the company at an enterprise value of $110M.

June Deal Announcements

Source: Boardroom Alpha

VGII Closes Merger with Grove Collaborative; GROV to trade tomorrow

Virgin Group Acquisition Corp. II (VGII) closes its merger with Grove Collaborative.The transaction included a $86M PIPE and $50M backstop; likely to see high redemptions. The sustainable consumer products company trades tomorrow on the NYSE as GROV.

SPAC Deal Termination: AKIC/ DNEG

Sports Ventures Acquisition Corp. (AKIC) and visual effects and animation company DNEG terminate deal due to “unfavorable market conditions.” AKIC will continue to look for another transaction.


Feutune Light Acquisition Corp. II (FLVU) prices $85M IPO. No business combination target noted. 

SPAC Daily Movers

Source: Boardroom Alpha

SPAC Calendar

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

<a href="" target="_self">Joanna Makris</a>

Joanna Makris

Joanna has been analyzing and investing in emerging technologies for over two decades, having led the Technology, Media, and Telecom research at several global investment banks, including Mizuho Securities and Canaccord Genuity. Navigating stock market volatility since it all began in 2000. Banjo player, artist, and frittata-maker.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Monthly SPAC Review

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SPAC Research & Analysis

Comera Life Sciences Debuts in the Red

Comera Life Sciences (CMRA), the maker of self-injectible biologics, deSPAC’d today, closing down 9%. An updated look at deSPAC count and redemption rates. And the rest of the day’s news in SPACs.

Starting the Week with 2 DAs

Starting the week off with 2 DAs– oil & gas and battery tech. And the rest of the day’s news in SPACs.

Comera Gets Approval, with Over 98% Redemptions

Squeeze alert: OTRA approves its merger with Comera Life Sciences, albeit with some of highest redemptions we’ve seen in a while (98.4%). And the rest of the day’s news in SPACs.

Know Who Drives Return Podcast

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.


The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.